Show simple item record

PATRIOT: A phase I study to assess the tolerability, safety and biological effects of a specific ataxia telangiectasia and Rad3-related (ATR) inhibitor (AZD6738) as a single agent and in combination with palliative radiation therapy in patients with solid tumours.

dc.contributor.authorDillon, MT
dc.contributor.authorBoylan, Z
dc.contributor.authorSmith, D
dc.contributor.authorGuevara, J
dc.contributor.authorMohammed, K
dc.contributor.authorPeckitt, C
dc.contributor.authorSaunders, M
dc.contributor.authorBanerji, U
dc.contributor.authorClack, G
dc.contributor.authorSmith, SA
dc.contributor.authorSpicer, JF
dc.contributor.authorForster, MD
dc.contributor.authorHarrington, KJ
dc.date.accessioned2018-08-09T10:45:09Z
dc.date.issued2018-08-01
dc.identifier.citationClinical and translational radiation oncology, 2018, 12 pp. 16 - 20
dc.identifier.issn2405-6308
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/2311
dc.identifier.eissn2405-6308
dc.identifier.doi10.1016/j.ctro.2018.06.001
dc.description.abstractPATRIOT is a phase I study of the ATR inhibitor, AZD6738, as monotherapy, and in combination with palliative radiotherapy. Here, we describe the protocol for this study, which opened in 2014 and is currently recruiting and comprises dose escalation of both drug and radiotherapy, and expansion cohorts.
dc.formatElectronic-eCollection
dc.format.extent16 - 20
dc.languageeng
dc.language.isoeng
dc.publisherELSEVIER IRELAND LTD
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.titlePATRIOT: A phase I study to assess the tolerability, safety and biological effects of a specific ataxia telangiectasia and Rad3-related (ATR) inhibitor (AZD6738) as a single agent and in combination with palliative radiation therapy in patients with solid tumours.
dc.typeJournal Article
dcterms.dateAccepted2018-06-06
rioxxterms.versionofrecord10.1016/j.ctro.2018.06.001
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by-nc-nd/4.0
rioxxterms.licenseref.startdate2018-08
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfClinical and translational radiation oncology
pubs.notesNo embargo
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology/Targeted Therapy
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Medicine Drug Development Unit (de Bono)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical Pharmacology – Adaptive Therapy
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine Drug Development Unit (de Bono)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Targeted Therapy
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology/Targeted Therapy
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Medicine Drug Development Unit (de Bono)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical Pharmacology – Adaptive Therapy
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine Drug Development Unit (de Bono)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Targeted Therapy
pubs.publication-statusPublished
pubs.volume12
pubs.embargo.termsNo embargo
icr.researchteamClinical Pharmacology – Adaptive Therapy
icr.researchteamMedicine Drug Development Unit (de Bono)
icr.researchteamTargeted Therapy
dc.contributor.icrauthorDillon, Magnus
dc.contributor.icrauthorBanerji, Udai
dc.contributor.icrauthorHarrington, Kevin


Files in this item

Thumbnail
Name:
PIIS2405630818300491.pdf
Size:
1.052Mb
Format:
PDF
Description:
Published version
View/Open

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0